-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
<>/* Style Definitions */ span.
ASC61 single drug showed significant anti-tumor efficacy in humanized mouse model and other animal models
"
Ascletis is committed to the R&D and commercialization of innovative drugs in the fields of viral diseases, nonalcoholic steatohepatitis/primary biliary cholangitis, tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors), etc.
(2) New coronary pneumonia drug pipeline: currently includes (i) marketed ritonavir oral tablet (100 mg); (ii) oral polymerase (RdRp) inhibitor ASC10; (iii) oral protease (3CLpro) inhibitor agent ASC11
Gan Lai has three clinical-stage nonalcoholic steatohepatitis drug candidates targeting fatty acid synthase (FASN), thyroid hormone ß receptor (THRß) and farnesoid X receptor (FXR) and three fixed-dose combinations preparation
For more information, please visit the website: .
ASC61 is a potent and highly selective oral PD-L1 small molecule inhibitor that blocks the PD-1/PD-L1 interaction by inducing the formation and endocytosis of PD-L1 dimers
.
ASC61 single drug showed significant anti-tumor efficacy in humanized mouse model and other animal models
Compared with PD-1/PD-L1 antibody injections, oral PD-L1 inhibitor ASC61 has the following advantages: (1) convenient administration, no need to go to the hospital for injection drugs; (2) combined with other oral antitumor drugs Form an all-oral treatment regimen; and (3) be able to adjust the dosage in a timely manner to better manage immune-related adverse events
.
"We are very pleased to submit the US clinical trial application for ASC61," said Dr.
Jinzi Wu, founder, chairman and chief executive officer of Ascletis, "We are advancing the combination of the fatty acid synthase (FASN) inhibitor ASC40 and bevacizumab in the treatment of relapsed The Phase III clinical trial in glioblastoma (rGBM), ASC61 as an oral PD-L1 small molecule inhibitor, will further strengthen Ascletis' oncology pipeline
.
"
About Song Li
Ascletis is an innovative R&D-driven biotechnology company listed on the Hong Kong Stock Exchange (1672.
HK), covering the complete value chain from new drug discovery and development to production and commercialization
.
Ascletis is committed to the R&D and commercialization of innovative drugs in the fields of viral diseases, nonalcoholic steatohepatitis/primary biliary cholangitis, tumors (oral tumor metabolic checkpoint and immune checkpoint inhibitors), etc.
1.
Viral diseases: (1) Hepatitis B (functional cure): Explore a treatment plan with subcutaneous injection of PD-L1 antibody ASC22 and Pegasys® as cornerstone drugs, combined with other target drugs, which is expected to be functional cure for hepatitis B bring about a major breakthrough
.
(2) New coronary pneumonia drug pipeline: currently includes (i) marketed ritonavir oral tablet (100 mg); (ii) oral polymerase (RdRp) inhibitor ASC10; (iii) oral protease (3CLpro) inhibitor agent ASC11
2.
Non-alcoholic steatohepatitis/primary biliary cholangitis: Ganlai, a wholly-owned subsidiary of Ascletis, focuses on the development and commercialization of innovative drugs in the field of non-alcoholic steatohepatitis
.
Gan Lai has three clinical-stage nonalcoholic steatohepatitis drug candidates targeting fatty acid synthase (FASN), thyroid hormone ß receptor (THRß) and farnesoid X receptor (FXR) and three fixed-dose combinations preparation
3.
Oncology (oral tumor metabolic checkpoint and immune checkpoint inhibitors): Ascletis has an innovative and differentiated pipeline in the field of tumor therapy, focusing on oral inhibitors of fatty acid synthase that play a key role in tumor lipid metabolism pipeline and a new generation of immune checkpoint inhibitors - oral PD-L1 small molecule inhibitor pipeline
.
4.
Expanded indications: Acne: ASC40 has been approved for Phase II clinical trials for new acne indications following the indications for nonalcoholic steatohepatitis and solid tumors
.
For more information, please visit the website: .
